Hot Investor Mandate: Private Equity Firm with $300M Fund Invests in North American Life Science Technologies with Strong China Market Potential, with Particular Interest in Vaccines

30 Aug

A private equity firm founded in 2003 with headquarters in the USA has previously invested in real estate, retail, and consumer products industries. However, the firm has recently focused on life science investment opportunities. The firm’s current fund is over $300M and the firm is planning to raise a $200M fund focused on life sciences and consumer products. The firm’s minimum investment begins at $5M, and the investment size depends on the stage of the targeted company. The firm primarily invests in later stage life science companies. The firm is looking for companies in North America and Canada and would seek distribution rights in China. The firm is actively looking for investment opportunities and plans to make 4-5 new investments as soon as possible. The firm would only seek to be the lead investor and will request a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of therapeutic assets but prefers companies that are into phase I of clinical trials or later. The firm is especially interested in vaccines including flu vaccines, Hepatitis A vaccine, Hepatitis B vaccine, and any other drugs for common diseases in China. The firm has a strong preference for later stage companies with products and pipelines that can directly produce and sell in China. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices. The firm is open to any phases in medical devices and therapeutics with a preference for those within human data. The most important consideration is the potential market in China.

The firm considers the management team’s character and entrepreneurial spirit. Team members who speak Mandarin may be a plus but is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: